HealthDay on MSN22h
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRCFor patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback